ReviewInnovation (Cambridge (Mass.))2020
Therapy of Primary Liver Cancer.
Review in Innovation (Cambridge (Mass.)), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed.
- Analysis of common treatment-related adverse events of donafenib and its correlation with efficacy: exploratory analysis of the ZGDH3 study.European journal of medical research · 2025Trial
- Wool Keratin-Engineered Manganese Nanozyme with Tumor Microenvironment-Adaptive Self-Cascade Capability for Hepatocellular Carcinoma Therapy.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- PLLA@PDA-DOX Nanobubbles for Ultrasound Imaging Combined Chemo-Photothermal Therapy.Biomolecules · 2026Article
- The adduct models of aflatoxins with DNA and effects on DNA polymerase Ⅳ.Journal of molecular modeling · 2026Article
- [Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026Article
- A new inject-embed 3D culture method enables the spheroid and aggregate formation from single or dual liver cancer cell types.Cancer cell international · 2026Article
- Identifying C1orf122 as a potential HCC exacerbated biomarker dependently of SRPK1 regulates PI3K/AKT/GSK3β signaling pathway.Genes & diseases · 2026Article
- Low SVEP1 in intrahepatic cholangiocarcinoma mediates phenotype switching-driven metastasis by Jag2/Notch1/Hes5.Cell death & disease · 2025Article
- Article
- Protein palmitoylation in hepatic diseases: Functional insights and therapeutic strategies.Journal of advanced research · 2025Review
- Role of MEX3A in tumorigenesis: Mechanisms, tumor‑specific effects and therapeutic implications (Review).International journal of molecular medicine · 2025Review
- SMYD5-BRD4 Interaction Drives Hepatocellular Carcinoma Progression: A Combined in Silico and Experimental Analysis.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Identification of matrix stiffness-related molecular subtypes in HCC via integrating multi-omics analysis and machine learning algorithms.Journal of translational medicine · 2025Article
- Global first-in-class drugs approved in 2023-2024: Breakthroughs and insights.Innovation (Cambridge (Mass.)) · 2025Review
- Single-cell landscape of dynamic changes in CD8Scientific reports · 2025Article
- Microbiome interplays in the gut-liver axis: implications for liver cancer pathogenesis and therapeutic insights.Frontiers in cellular and infection microbiology · 2025Review
- The pivotal role of cytokines in liver disease pathogenesis and therapeutic potential.Frontiers in immunology · 2025Review
- A bibliometric analysis of liver cancer bone metastases: advances in mechanisms of occurrence and treatment options.Frontiers in oncology · 2025Review
- The Protective Role of miR-125b in Hepatocellular Carcinoma: Unraveling Tumor-Suppressive Mechanisms.Current molecular medicine · 2025Review
- PPM1G and its diagnostic, prognostic and therapeutic potential in HCC (Review).International journal of oncology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary liver cancer (PLC) is a fatal disease that affects millions of lives worldwide. PLC is the leading cause of cancer-related deaths and the incidence rate is predicted to rise in the coming decades. PLC can be categorized into three major histological subtypes: hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), and combined HCC-ICC. These subtypes are distinct with respect to epidemiology, clinicopathological features, genetic alterations, and clinical managements, which are thoroughly summarized in this review. The state of treatment strategies for each subtype, including the currently approved drugs and the potential novel therapies, are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.